Versican is a potential therapeutic target in docetaxel-resistant prostate cancer

In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant P...

Full description

Saved in:
Bibliographic Details
Published in:Oncoscience 2015-03, Vol.2 (2), p.193-204
Main Authors: Arichi, Naoko, Mitsui, Yozo, Hiraki, Miho, Nakamura, Sigenobu, Hiraoka, Takeo, Sumura, Masahiro, Hirata, Hiroshi, Tanaka, Yuichiro, Dahiya, Rajvir, Yasumoto, Hiroaki, Shiina, Hiroaki
Format: Article
Language:English
Subjects:
Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant PC-3 cell line (DR-PC3). In DR-PC3 cells, DT therapy stronger inhibited proliferation/viability than docetaxel alone. Based on gene ontology analysis, we found versican as a selective gene. This result with the findings of cDNA microarray and validated by quantitative RT-PCR. In addition, the effect of DT therapy on cell viability was the same as the effect of docetaxel plus versican siRNA. In other words, silencing of versican can substitute for thalidomide. In the clinical setting, versican expression in prostate biopsy samples (before DT therapy) correlated with PSA reduction after DT therapy (p
ISSN:2331-4737
2331-4737
DOI:10.18632/oncoscience.136